Immunovia完成了对次基因胰腺癌试验的验证,启动了大规模的临床研究。 Immunovia completes validation of next-gen pancreatic cancer test, launching large-scale clinical study.

Immunovia成功地完成了对下一代早期胰腺癌试验的分析验证,显示了精确度和灵敏度等很强的性能指标。 Immunovia has successfully completed analytical validation of its next-generation test for early-stage pancreatic cancer, demonstrating strong performance metrics such as precision and sensitivity. 验证工作使用了自动ELISA分析仪,提高了比以往方法的效率。 The validation utilized an automated ELISA analyzer, improving efficiency over prior methods. 该公司发起了一项大规模的临床研究,以进一步评估测试在检测第1和第2阶段胰腺癌方面的准确性,预计到2024年12月将得出结果。 The company has launched a large-scale clinical study to further evaluate the test's accuracy for detecting stage 1 and 2 pancreatic cancer, with results anticipated by December 2024.